Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease
An Observational, Practice-Based, Open Label, Feasibility Study to Observe the Efficacy and Safety of Intramuscular Administration of Stempeucel® in Malaysian Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease.
Cell Biopeutics Resources Sdn Bhd
10 participants
Jan 1, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this observational, practice-based feasibility study is to observe the efficacy and safety of intramuscular administration of Stempeucel® in Malaysian patients with critical limb ischemia (CLI) due to peripheral arterial disease. The main questions it aims to answer are: * Can intramuscular administration of Stempeucel® reduce symptoms of CLI due to peripheral arterial disease while improving the healing rate and functional outcomes? * Does intramuscular administration of Stempeucel® causes any serious adverse events in CLI due to peripheral arterial disease patients? Study patients will be assessed by the PI before administering the Stempeucel® for any other organ with inflammation. The study patients will also be followed up to the duration of 1 year after study treatment administration for safety and efficacy assessment.
Eligibility
Inclusion Criteria6
- Patients between 18-65 years old
- Patients diagnosed with atherosclerotic peripheral arterial disease
- Patients not eligible for or have failed surgical or percutaneous revascularization (No option patients)
- Patients with at least one ulcer (between 0.5 to 10 cm2 size)
- Ankle brachial pressure index (ABPI) ≤ 0.6 (toe brachial index (TBI) if ABPI out of range; TBI ≤ 0.5)
- Patients who are able and willing to provide consent and agrees to comply with study procedures and follow-up evaluations
Exclusion Criteria4
- Patients diagnosed with Buerger's disease by Shionoya criteria
- Patients eligible for surgical or percutaneous revascularization
- Patients with a history of participating in another stem cell trial or therapy within 3 months
- Patients who are unsuitable to participate the clinical trial as determined by investigators
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
• Ex-vivo cultured allogeneic mesenchymal stem cells (MSCs) supplied in cryo-bags consisting of 150 or 200 million, suspended in 50 ml of Plasmalyte A containing 1.5% human serum albumin (HSA) and 3% dimethyl sulfoxide (DMSO).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05854641